Loading...

KYTX KYVERNA THERAPEUTICS INC Product Launches 8-K Filing

KYVR

KYTX

KYVERNA THERAPEUTICS INC

(KYTX)

2026 8-K

CFO Appointment

Business Update Issued

Management Change

Positive Trial Results

Positive Trial Results

Positive Clinical Data

Quarterly Earnings Update

Board Appointments

Management Change

Management Change

Stock Offering Details

Positive Data Release

Positive Trial Results

Business Update

Loan Agreement Funded

Positive Trial Results

Positive Data Release

Financial Statements

Stock Sale Agreement

Financial Results

Management Appointment

Strategic Priorities

Management Change

Financial Update

Director Appointment

Management Changes

External Links:

On April 20, 2026, Kyverna Therapeutics announced promising long-term results from its Phase 2 trial for a treatment targeting generalized myasthenia gravis, with a conference call scheduled for April 22, 2026, to discuss these findings.

AI Assistant

KYVERNA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.